These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 16453992)

  • 41. Rationale for targeted rather than population based screening with C-reactive protein using the National Health and Nutrition Examination Survey (1999 to 2002).
    Guttormsen BN; Stein JH; McBride PE; Cullen MW; Gangnon R; Keevil JG
    Am J Cardiol; 2007 Oct; 100(7):1130-3. PubMed ID: 17884376
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
    Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Bays HE
    Curr Med Res Opin; 2007 Sep; 23(9):2125-33. PubMed ID: 17655813
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2.
    Santos RD; Waters DD; Tarasenko L; Messig M; Jukema JW; Ferrières J; Verdejo J; Chiang CW;
    Am Heart J; 2009 Nov; 158(5):860-6. PubMed ID: 19853709
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Estimating the impact of adding C-reactive protein as a criterion for lipid lowering treatment in the United States.
    Woloshin S; Schwartz LM; Kerin K; Welch HG
    J Gen Intern Med; 2007 Feb; 22(2):197-204. PubMed ID: 17356986
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Treatment of hypercholesterolemia in secondary prevention. Statement of the Italian National Association of Hospital Cardiologists].
    Marchioli R; Valagussa F; Vanuzzo D; Giannuzzi P; Pede S; Schweiger C
    G Ital Cardiol; 1998 Apr; 28(4):409-15. PubMed ID: 9616858
    [No Abstract]   [Full Text] [Related]  

  • 46. Estimate of requirements for detection and treatment of hypercholesterolemia in U.S. Army aviators.
    Burke TJ
    Aviat Space Environ Med; 1991 Dec; 62(12):1174-9. PubMed ID: 1755800
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of a global risk educational tool on primary coronary prevention: the Atherosclerosis Assessment Via Total Risk (AVIATOR) study.
    Jacobson TA; Gutkin SW; Harper CR
    Curr Med Res Opin; 2006 Jun; 22(6):1065-73. PubMed ID: 16846539
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differences between clinical trial efficacy and real-world effectiveness.
    Davidson MH
    Am J Manag Care; 2006 Nov; 12(15 Suppl):S405-11. PubMed ID: 17112328
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current questions regarding the use of statins in patients with coronary heart disease.
    Rallidis LS; Lekakis J; Kremastinos DT
    Int J Cardiol; 2007 Nov; 122(3):188-94. PubMed ID: 17399827
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia.
    Patel JV; Hughes EA
    Int J Clin Pract; 2006 Aug; 60(8):914-21. PubMed ID: 16893434
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).
    Ballantyne CM; Weiss R; Moccetti T; Vogt A; Eber B; Sosef F; Duffield E;
    Am J Cardiol; 2007 Mar; 99(5):673-80. PubMed ID: 17317370
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia.
    Stein EA; Amerena J; Ballantyne CM; Brice E; Farnier M; Guthrie RM; Harats D; Ma PT; Le Maulf F; Melezínková H; Gold A; Sager P
    Am J Cardiol; 2007 Nov; 100(9):1387-96. PubMed ID: 17950795
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
    Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
    Bays HE; Davidson M; Jones MR; Abby SL
    Am J Cardiol; 2006 Apr; 97(8):1198-205. PubMed ID: 16616026
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Implementing the National Cholesterol Education Program's update to the ATP III report.
    Palmieri J
    Manag Care Interface; 2005 Sep; 18(9):44-9. PubMed ID: 16209139
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Managing borderline levels of risk for coronary heart disease: two illustrative case presentations.
    Ansell BJ
    J Am Osteopath Assoc; 2001 Sep; 101(9 Suppl):S12-6. PubMed ID: 11575042
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Case 1: a patient with elevated low-density lipoprotein cholesterol.
    Friedewald VE; Gotto AM
    Am J Cardiol; 2000 Jan; 85(1):131. PubMed ID: 11078257
    [No Abstract]   [Full Text] [Related]  

  • 58. Hypercholesterolemia. Causes, significance, and diagnosis.
    Memmer MK
    Prog Cardiovasc Nurs; 1989; 4(2):33-9. PubMed ID: 2740322
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Primary and secondary risk factors for coronary heart disease: their role in prevention.
    Wilhelmsen L
    Med J Malaysia; 1977 Jun; 31(4):296-301. PubMed ID: 927236
    [No Abstract]   [Full Text] [Related]  

  • 60. New guidelines from the National Cholesterol Education Program: what is the impact on risk assessment?
    Lowden JA
    J Insur Med; 2002; 34(1):26-30. PubMed ID: 15303591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.